pharma · Solid Tumors · Primary Dysmenorrhea
Topiloric/Uriadec
Topiloric/Uriadec clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- SOUTH SAN FRANCISCO, CA, JP
- Employees
- 2
- Programs
- 12
- Drugs
- 7
- Patents
- 52
Topiloric/Uriadec projects
12 ClinicalTrials.gov programs sponsored by Topiloric/Uriadec.
Topiloric/Uriadec has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AgnoMed
Topiloric/Uriadec
Primary Dysmenorrhea
1 trial -
ORIC-114
Topiloric/Uriadec
Solid Tumors
1 trial -
ORIC-114
Topiloric/Uriadec
Solid Tumors
1 trial -
ORIC-101
Topiloric/Uriadec
Healthy Volunteers
2 trials -
ORIC-101
Topiloric/Uriadec
Prostatic Neoplasms
1 trial -
ORIC-101
Topiloric/Uriadec
Solid Tumor
1 trial -
ORIC-114
Topiloric/Uriadec
Food Effect in Healthy Participants
1 trial -
ORIC-114 Dose 1 + amivantamab
Topiloric/Uriadec
Solid Tumors
1 trial -
ORIC-533
Topiloric/Uriadec
Relapsed or Refractory Multiple Myeloma
1 trial -
ORIC-944
Topiloric/Uriadec
Metastatic Prostate Cancer
1 trial -
Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.
Topiloric/Uriadec
Prostate cancer
1 trial -
SilMAKin
Topiloric/Uriadec
chronic liver disease
1 trial
Frequently asked questions
How many clinical projects does Topiloric/Uriadec have?
12 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.